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Abstract: Ovarian cancer is the 8th most common cancer in women, and the 5th leading cause of cancer-related 
deaths among women in the United States. Statins have been shown to have promising anti-tumorigenic activity 
in many types of cancers. We sought to determine the effects of atorvastatin (ATO) on cell proliferation in ovarian 
cancer and identify the mechanisms by which ATO inhibits cell growth in this disease. ATO inhibited cell proliferation 
of both the Hey and SKOV3 ovarian cancer cells in a dose-dependent manner. The anti-proliferative activity of ATO 
in the ovarian cancer cell lines was associated with induction of apoptosis, autophagy, cellular stress and cell cycle 
G1 arrest via inhibition of AKT/mTOR and activation of the MAPK pathways. Moreover, ATO inhibited cell adhesion 
and invasion as well as decreased expression of VEGF and MMP9. c-Myc was downregulated in ovarian cancer cells 
exposed to ATO. Inhibition of c-Myc by JQ1 synergistically increased the sensitivity of ovarian cancer cells to ATO. 
This data suggests that ATO may have a therapeutic role in the treatment of ovarian cancer and warrant further 
exploration in clinical trials.
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Introduction
Ovarian cancer has the highest mortality of all 
gynecologic cancers, with a dismal 5 year over-
all survival of only 46% [1]. This makes ovarian 
cancer the 5th leading cause of cancer deaths 
in women [1-3]. Despite aggressive surgery and 
adjuvant treatment, a significant proportion of 
women with ovarian cancer will ultimately 
develop disease recurrence and chemo-resis-
tance [4]. Currently there are no chemothera-
peutic agents that effectively target chemo-
resistant or late stage ovarian cancer [4, 5]. 
The development of new, targeted therapies is 
paramount to decreasing ovarian cancer relat-
ed mortality and improving overall survival. 
The mevalonate pathway serves as the main 
pathway for cholesterol production. This path-
way also produces numerous non-steroid iso-
prenoid side products that are critical for func-
tioning in both normal and cancer cells. These 
isoprenoid derivatives, including cholesterol, 
dolichol, ubiquinone, isopentenyladenine, gera-
nylgeranyl pyrophosphate and farnesyl pyro-
phosphate, have been shown to promote tumor 
cell growth, differentiation, migration, and intra-
cellular trafficking [6, 7]. Transformed malig-
nant cells are also highly dependent on the 
mevalonate pathway for the synthesis of lipid 
moieties critical for cell proliferation, mem-
brane integrity, cell cycle progression and cell 
signaling [8]. Upregulated activity of the meval-
onate pathway has been shown in a range of 
different cancers, including ovarian cancer [6, 
9, 10]. Thus, inhibition of the mevalonate path-
way using HMG-CoA reductase inhibitors should 
result in decreased levels of mevalonate and its 
downstream products, and thus, may have sig-
nificant inhibitory influences on cancer cell 
growth [9, 11, 12]. 
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HMG-CoA reductase (3-hydroxy-3-methylglu-
tharyl-coenzyme A reductase, HMGCR), which 
is responsible for cholesterol and isoprenoid 
derivative production, is the rate limiting 
enzyme in the mevalonate pathway. Inhibition 
of HMGCR activity results in decreased levels 
of mevalonate and its downstream products 
that affects critical cell functions such as mem-
brane integrity, cell signaling, protein synthesis 
and cell cycle progression [8, 13]. The level of 
HMGCR has been associated with carcinogen-
esis and tumor progression in several cancers 
[10, 13]. Targeting HMGCR using statins 
increases tumor specific apoptosis, induces 
cell cycle arrest and inhibits tumor growth [11, 
12]. The expression of HMGCR has been found 
to be an independent predictor of prolonged 
recurrence-free survival in ovarian cancer 
[9-12]. 
Statins are a class of HMGCR inhibitors tradi-
tionally used to treat hyperlipidemia and to 
decrease the risk of cardiovascular disease [8]. 
In the United States, nearly 30% of adults age 
40-75 take a statin [14]. Epidemiologic studies 
have shown that long term statin use is associ-
ated with a decreased risk of developing ovari-
an cancer [14-16]. Our group has recently 
shown that simvastatin significantly inhibits cell 
proliferation and induces apoptosis and cell 
cycle arrest in endometrial cancer and ovarian 
cancer in vitro and in vivo, suggesting that sim-
vastatin may serve as a potential agent in the 
management of gynecologic malignancies [11, 
12]. 
Atorvastatin (ATO) is the most commonly used 
statin approved for cholesterol reduction and 
has a very favorable toxicity profile [17]. This 
agent is more effective at lowering LDL and 
reducing the risk of peripheral artery disease 
and cardiovascular disease than simvastatin 
[18]. ATO’s main side effects are GI disturbanc-
es, which are usually temporary. As a class of 
drugs, statins are known for causing myalgias; 
however, ATO causes appreciably fewer myal-
gias than simvastatin [18, 19]. Previous epide-
miological studies indicate that ATO may be 
associated with a reduced risk of developing 
cancers, and animal studies have found that 
ATO effectively inhibits tumor growth in breast, 
prostate, pancreatic and liver cancer [20-24]. 
Given that ATO has demonstrated more benefi-
cial effects than simvastatin in the manage-
ment of lowering lipid levels and reducing side 
effects, ATO warrants further investigation as a 
potential therapeutic agent in ovarian cancer. 
Thus, the objective of this study was to explore 
the effect of ATO on growth, apoptosis and 
adhesion/invasion in human ovarian cancer 
cell lines.
Methods
Cell culture and reagents
Two ovarian cancer cell lines, Hey and SKOV3, 
were used for all experiments. The Hey cells 
were grown in RPMI 1640 medium supplement-
ed with 5% fetal bovine serum, 100 units/ml 
penicillin and 100 ug/ml streptomycin under 
5% CO2. The SKOV3 cells were grown in DMEM 
supplemented with 10% fetal bovine serum, 
300 mM l-glutamine, 10,000 U/ml penicillin 
and 10,000 μg/ml streptomycin under 5% CO2. 
ATO, RNase and RIPA buffer were purchased 
from Sigma (St. Louis, MO). Antibodies to ph- 
osphorylated-AKT (Ser473), phosphorylated-
p44/42 MAPK (Thr202/Tyr204), phosphorylat-
ed-S6 (Ser235/236), c-Myc, PERK, Bip, BCL-2, 
MCL-1, PARP, ATG3, ATG6, cleaved PARP, 
β-actin, pan-AKT, pan-p44/42 MAPK, pan-S6, 
VEGF and MMP9 were obtained from Cell 
Signaling Technology (Beverly, MA). The Annexin 
V FITC kit was purchased from BioVision 
(Mountain View, CA). JQ1 was kindly gifted by Dr 
James E. Bradner (Harvard Medical School, 
MA). Enhanced chemiluminescence western 
immunoblotting detection reagents were pur-
chased from Amersham (Arlington Heights, IL). 
All other chemicals were purchased from 
Sigma. 
Cell proliferation assay
The Hey and SKOV3 cells were plated and 
grown in 96-well plates at a concentration of 
5000 cells/well for 24 hours. Cells were then 
treated with varying concentrations of ATO for 
72 hours. After the addition of MTT dye (5 mg/
mL), the 96-well plates were incubated for 1-2 
hours at 37°C. 100 uL of DMSO was added to 
the plates in order to terminate the MTT reac-
tion. The plates were read by measuring absorp-
tion at 595 nm. The effect of ATO was calculat-
ed as a percentage of control cell growth 
obtained from phosphate-buffered saline (PBS 
1%) treated cells grown in the same 96-well 
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plates. Each experiment was repeated three 
times to assess for consistency of results. 
Colony formation assay
The Hey and SKOV3 cells growing in log phase 
were seeded in 6 cm dishes (800 cells/dish) in 
their standard growth medium. Cells were 
allowed to adhere for 24 hours, and then were 
treated with ATO for 24 hours. The cells were 
cultured at 37°C for 14 days with medium 
changes every third or fourth day. Cells were 
stained with 0.5% crystal violet, and colonies 
were counted under the microscope. Each 
experiment was repeated three times for con-
sistency of results
Cell cycle analysis 
The effect of ATO on cell cycle progression was 
assessed using Cellometer (Nexcelom, Lawren- 
ce, MA). Cells were plated at a density of 2 × 
105 cells/well in 6-well plates overnight and 
then treated with varying concentrations of ATO 
for 48 hours. Cells were collected by 0.05% 
trypsin (Gibco Grand Island, NY), washed with 
PBS solution, fixed in a 90% methanol solution 
and then stored at -20°C until cell cycle analy-
sis was performed. On the day of analysis, the 
cells were washed with PBS and centrifuged, 
resuspended in 50 ul RNase A solution (250 
ug/ml) with 10 mM EDTA, followed by incuba-
tion for 30 min at 37°C. After incubation, 50 µl 
of propidium iodide (PI) staining solution (2 mg/
ml PI, 0.1 mg/ml Azide and 0.05% Triton X-100) 
was added to each tube and incubated for 10 
min in the dark. The cells were assessed by 
Cellometer. The results were analyzed using 
FCS4 express software (Molecular Devices, 
Sunnyvale, CA). Each experiment was repeated 
at least twice for consistency of response.
Annexin V assay
The effect of ATO on cell apoptosis was detect-
ed using the Annexin-V FITC kit. Briefly, 2 × 105 
cells/well were seeded into 6-well plates over-
night and then the cells were cultured in media 
with varying concentrations of ATO for 24 hours. 
The cells were collected by 0.25% trypsin with-
out EDTA. After PBS washing, cells were resus-
pended in 100 ul of Annexin-V and PI dual-stain 
solution (0.1 ug of Annexin-V FITC and 1 ug of 
PI) for 15 min in the dark. Apoptotic cells were 
detected by Cellometer. The results were ana-
lyzed by FCS4 express software. Each experi-
ment was repeated at least twice for consis-
tency of response.
Reactive oxygen species (ROS) assay
ROS generation was assessed using the ROS-
sensitive fluorescence indicator, DCFH-DA. To 
determine intracellular ROS scavenging activi-
ty, the Hey and SKOV3 cells (1.0 × 104 cells/
well) were seeded in black 96-well plates. After 
24 hours, the cells were treated with ATO for 24 
hours to induce ROS generation. After the cells 
were incubated with DCFH-DA (20 μM) for 30 
minutes, the fluorescence intensity was mea-
sured at an excitation wavelength of 485 nm 
and an emission wavelength of 530 nm using a 
fluorescence microplate reader. All experi-
ments were performed in duplicate to assess 
for consistency of response. 
Adhesion assay 
Each well in a 96-well plate was coated with 
100 ul laminin-1 (10 ug/ml) and incubated at 
37°C for 1 hour. The fluid was then aspirated, 
and 200 ul blocking buffer was added to each 
well for 45-60 min at 37°C. The wells were then 
washed with PBS, and the plate was allowed to 
chill on ice. Next, 2.5 × 103 cells were added 
with PBS and varying concentrations of ATO 
directly. The plate was then allowed to incubate 
at 37°C for 2 hours. After this period, the medi-
um was aspirated, and cells were fixed by 
directly adding 100 ul of 5% glutaraldehyde. 
The plates were then incubated for 30 min at 
room temperature. Adherent cells were washed 
with PBS and stained with 100 ul of 0.1% crys-
tal violet for 30 minutes. The cells were then 
washed repeatedly with water, and 100 ul of 
10% acetic acid was added to each well to solu-
bilize the dye. After 5 minutes of shaking, the 
absorbance was measured at 570 nm using a 
micro-plate reader from Tecan (Morrisville, NC). 
Each experiment was repeated at least twice 
for consistency of response.
Invasion assay
Cell invasion assays were performed using 
96-well HTS transwells (Corning Life Sciences, 
Durham, NC) coated with 0.5-1 × BME (Trevigen, 
Gaithersburg, MD). The Hey and SKOV3 cells 
(50,000 cells/well) were starved for 12 hours 
and then seeded in the upper chambers of the 
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wells in 50 μl FBS-free medium. The lower 
chambers were filled with 150 μl standard 
medium with ATO. The plates were incubated 
for 16 hours at 37°C to allow invasion into the 
lower chamber. After washing the upper and 
lower chambers with PBS, 100 ul Calcein AM 
solution was added into the lower chambers 
and incubated at 37°C for 30-60 min. The 
lower chamber plate was measured by the 
plate reader for reading fluorescence at EX/EM 
485/520 nM. Each experiment was repeated 
at least twice for consistency of response.
Western immunoblotting
The Hey and SKOV3 cells were plated at 2 × 105 
cells/well in 6 well plates in their corresponding 
medium and were treated for 24 hours with 
ATO. Cell lysates were prepared in RIPA buffer 
(1% NP40, 0.5 sodium deoxycholate and 0.1% 
SDS) plus PhosStop. Equal amounts of protein 
were separated by gel electrophoresis and 
transferred onto a PVDF membrane. The mem-
brane was blocked with 5% nonfat dry milk and 
then incubated with a 1:1000 dilution of pri-
mary antibody overnight at 4°C. The membr- 
ane was then washed and incubated with a 
secondary peroxidase conjugated antibody for 
1 hour after washing. Antibody binding was 
detected using an enhanced chemilumines-
cence detection buffer by Alpha Innotech imag-
ing system (San Leandro, CA). Each experiment 
was repeated three times to assess for consis-
tency of results. 
Statistical analysis
Data are presented as a mean ± the standard 
error of the mean. Comparisons between 
groups were determined with the two-sided 
unpaired student’s t-test using GraphPad soft-
ware (La Jolla, CA USA). A value of P < 0.05 was 
considered significant. The combination-index 
(CI) methods, derived from the median-effect 
principle of Chou and Talalay, were used to 
define the pharmacologic interaction between 
the ATO and JQ1. CI < 1 or CI > 1 indicates syn-
ergism or antagonism, respectively.
Results
The effect of ATO on cell proliferation in ovar-
ian cancer cells
The effects of ATO on cell proliferation were 
examined in the SKOV3 and Hey ovarian cancer 
cell lines. Both cell lines were exposed to vary-
Figure 1. ATO inhibited the proliferation of ovarian cancer cells. The Hey and SKOV3 cells were cultured for 24 hours 
and then treated with varying concentrations of ATO in 96 well plates for 72 hours. Cell proliferation was assessed 
by MTT assay (A). The Hey and SKOV3 cells were seeded at low density in 6 cm dishes and treated with ATO for 24 
hours. The cells were cultured for 14 days with medium changes every third or fourth day. Colonies were visualized 
by crystal violet staining (B). Morphologies of the Hey and SKOV3 cells after treatment of ATO for 48 hours (C). The 
effect of ATO on HMGCR was examined by Western blot analysis. ATO treatment resulted in a dose-dependent de-
crease in expression of HMGCR protein in both cell lines (D). Each experiment was performed three times.
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ing doses of ATO (1-250 uM) for 72 hours. MTT 
assay showed that ATO decreased cell prolifer-
ation in a dose-dependent manner in both cell 
lines after 72 hours of treatment, with IC50 val-
ues of 122 uM for the Hey cells and 80 uM for 
the SKOV3 cells (Figure 1A). 
Given that the colony formation assay is an 
excellent indicator of long term tumor cell sur-
vival, a colony formation assay was performed 
to investigate the long-term effect of ATO on 
cell growth in both cell lines. As shown in Figure 
1B, the colony-forming ability of Hey and SKOV3 
was reduced by 88% and 75%, respectively, 
after exposure to 150 uM of ATO for 14 days. 
This data suggest that ATO effectively decreas-
es cell growth in ovarian cancer cells. The 
effects of ATO on cellular morphology in both 
cell lines is shown in Figure 1C. Control cells 
the Hey cells, G1 arrest increased from 49% in 
control cells to 68% in cells treated with 150 
uM of ATO. In the SKOV3 cells, treatment with 
ATO increased G1 arrest from 44% in controls 
to 62% at a dose of 150 μM. 
We then examined the effects of ATO on cell 
apoptosis using the Annexin V assay, which 
detects early apoptotic cells by monitoring fluo-
rescent labeled Annexin V. The Hey and SKOV-3 
cells were treated with ATO at varying concen-
trations (1-150 uM) for 18 hours. ATO increased 
the percentage of cells in apoptosis in a dose-
dependent manner in both the Hey and SKOV3 
cell lines, with slightly more apoptosis seen in 
the Hey cells (Figure 2B).
We also assessed the effects of ATO on the 
apoptotic proteins, MCL-1, BCL-2 and PARP in 
Figure 2. ATO induced cell cycle G1 arrest and apoptosis in ovarian cancer 
cells. The Hey and SKOV3 cell lines were treated with the indicated doses of 
ATO (1-150 uM) for 24 hours. Cell cycle analysis was performed by Cellometer. 
ATO markedly induced cell cycle G1 arrest in both cell lines in a dose depen-
dent manner (A). Apoptosis was detected using Annexin-V FITC assay in both 
cell lines after 18 hours of treatment. ATO increased Annexin V expression 
in the Hey and SKOV3 cells (B). Western blotting indicated treatment ATO for 
18 hours decreased the expression of MCL-1 and increased Cleaved PARP 
expression in both cell lines (C). Data are shown as mean + SEM of two experi-
ments (*P < 0.05). Each experiment was performed three times.
were round or oval shape 
with large, clear nuclei. 
Following ATO treatment for 
48 hours, the treated cells 
shrunk and displayed a 
rounder shape. The size and 
density of the treated cells 
were also greatly decreased.
To assess the effect of ATO 
on HMGCR, we treated Hey 
and SKOV3 cells with varying 
doses of ATO for 24 hours. 
Western blotting results sh- 
owed a significant decrease 
in the expression of HMGCR 
in both cell lines with atorv-
astatin treatment (Figure 
1D). 
Atorvastatin induced cell 
cycle arrest and apoptosis
To assess the underlying 
mechanism of growth inhibi-
tion of the ovarian cancer 
cells by ATO, the cell cycle 
profile was analyzed by 
Cellometer after treating the 
Hey and SKOV3 cell lines 
with varying doses of ATO. 
ATO induced G1 phase arrest 
and decreased S phase in 
both cell lines after 24 hours 
of treatment (Figure 2A). In 
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Figure 3. ATO caused cellular stress and autophagy in ovarian cancer cells. 
The Hey and SKOV3 cell lines were treated with ATO at different concentra-
tions for 24 hours and reactive oxygen species (ROS) levels were determined 
using DCFH-DA dye on a plate reader (A). PERK and Bip were determined by 
Western immunoblotting after exposure to ATO for 24 h (B). Autophagy in the 
Hey and SKOV3 cell lines was analyzed by immunoblotting after treatment 
with ATO for 24 hours. ATO increased the expression of ATG3 and ATG6 in 
the cells (C). Each experiment was performed three times. (*P < 0.05, **P 
< 0.01).
both ovarian cancer cell 
lines. Our western blotting 
results showed that ATO 
decreased MCL-1 expression 
in both cell lines, and 
increased BCL-2 expression 
in the Hey cells and reduced 
BCL-2 expression in the 
SKOV3 cells. We also found 
that ATO treatment increased 
cleaved PARP protein expres-
sion at dose of 150 uM in 
both cell lines (Figure 3C), 
suggesting that inducing 
mitochondrial apoptosis may 
be one mechanism by which 
ATO inhibits cell proliferation 
in ovarian cancer cells. 
These data, combined with 
the cell cycle results, indi-
cate that ATO inhibits cell 
proliferation through induc-
tion of cell cycle G1 arrest 
and apoptosis in ovarian 
cancer cells.
ATO induces cell stress and 
autophagy
Increased reactive oxygen 
species (ROS) can cause 
damage to a variety of cellu-
lar components and eventu-
ally lead to cell death in can-
cer cells [25]. The effect of 
ATO on ROS production in 
the Hey and SKOV3 cells was 
evaluated. ATO increased 
ROS levels in both cell lines 
in a dose-dependent manner 
after 24 hours of treatment. 
The difference in ROS levels 
between the ATO doses of 
50 and 150 uM and control 
were statistically different in 
both cell lines (Figure 3A). 
Additionally, alternations in 
the expression of the cellular 
stress proteins, Bip and 
PERK, was analyzed by west-
ern immunoblotting. Treat- 
ment with ATO for 24 hours 
resulted in a significant in- 
crease in expression of Bip 
Figure 4. Effect of ATO on MAPK and AKT/mTOR pathways in ovarian cancer 
cells. The Hey and SKOV3 cells were treated with ATO at different doses for 
24 h. Phosphorylated-p42/44, phosphorylated-AKT and phosphorylated-pS6 
were assessed by Western blotting. ATO inhibited the activity of AKT/mTOR 
pathway in both cell lines, increased MAPK activity in the Hey cells and de-
creased phosphorylation of p42/44 in the SKOV3 cells. Each experiment was 
performed two times.
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and PERK in both cell lines. At a dose of 150 
μM, ATO increased Bip expression 2.36-fold in 
the Hey cells and 1.92-fold in the SKOV3 cells. 
Similarly, 150 uM of ATO increased PERK 
expression by 1.41-fold in the Hey cells and 
1.18-fold in the SKOV3 cells.
Conventional cytotoxic drugs and irradiation 
have been shown to induce autophagy in can-
cer cells [26]. The effect of ATO on autophagy in 
both cell lines was examined. The Hey and 
SKOV3 cells were treated with different con-
centrations of ATO for 24 hours. Western immu-
noblotting results showed that ATO induced 
ATG3 and ATG6 expression in a dose-depen-
dent manner in both cell lines. At a dose of 50 
uM, ATO increased ATG3 expression by 2.1 fold 
and ATG6 expression by 3.2 fold in the Hey 
cells. Similarly, ATG3 expression was increased 
inhibition of cell proliferation by ATO may involve 
different pathways in different ovarian cancer 
cells.
ATO inhibited cell adhesion and invasion 
In order to determine the effect of ATO on the 
invasive ability of ovarian cancer cells, a lam-
inin adhesion assay and a transwell invasion 
system were employed. Incubation of the Hey 
and SKOV3 cells with ATO (1, 50 and 150 uM) 
for 2 hours showed significant inhibition of cell 
adhesion (Figure 5A). ATO significantly blocked 
ovarian cancer cell invasion after 16 hours of 
treatment as determined by the transwell inva-
sion assay (Figure 5B). Inhibition of cell inva-
sion was dose-dependent in both cell lines. 
Since vascular endothelial growth factor (VEGF) 
and matrix metalloproteinase (MMPs) are 
important mediators of angiogenesis and inva-
Figure 5. ATO decreased adhesion and invasion in ovarian cancer cells. The 
Hey and SKOV3 cell lines were cultured for 24 hours and then treated as 
indicated with ATO in a laminin-coated 96 well plate for 2 hours to assess ad-
hesion (A) or a BME coated 96 transwell plate for 16 hours to assess invasion 
(B), respectively. The data represents relative inhibition in each cell line. VEGF 
and MMP9 was measured by Western blotting in cell lysates after a 24 hour 
exposure to ATO. ATO decreased the expression of VEGF and MMP9 expres-
sion in a dose-dependent manner (C). Each experiment was performed three 
times. (*P < 0.05, **P < 0.01).
by 1.3 fold and ATG expres-
sion by 1.6 fold in the SKOV3 
cells. These results suggest 
that in addition to cell cycle 
G1 arrest and apoptosis, 
autophagy may be responsi-
ble for inhibition of cell 
growth induced by ATO in 
ovarian cancer cells.
The effect of ATO on AKT/
mTOR and MAPK pathways 
Given that the AKT/mTOR 
and MAPK pathways have 
been shown to regulate glu-
cose and lipid metabolism in 
cancer cells, we investigated 
whether these pathways 
were involved in the anti-pro-
liferative effects of ATO in 
ovarian cancer cells. Western 
blotting showed that phos-
phorylation of S6 was re- 
pressed by ATO in a dose 
dependent manner after 24 
hours of treatment in both 
cell lines (Figure 4). ATO 
increased phosphorylation 
of AKT in the Hey cells, and 
decreased phosphorylation 
of ERK in the SKOV3 cells. 
Together, these results sug-
gest that ATO targets the 
mTOR pathway; however, the 
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sion in ovarian cancer, we sought to determine 
the effects of ATO on production of VEGF and 
MMP9 in both cell lines. ATO significantly 
reduced the expression of VEGF and MMP9 
after 24 hours of treatment (Figure 5C). These 
results suggest that ATO may function to inhibit 
adhesion and invasion and decrease angiogen-
esis, as well as inducing apoptosis, cell cycle 
arrest and cellular stress in the Hey and SKOV3 
cell lines. 
c-Myc was involved in inhibition of cell growth 
by ATO 
c-Myc is a central oncogene that acts to control 
cell proliferation, differentiation, metabolism 
and apoptosis in ovarian cancer. It has been 
previously shown that inhibition of HMG-COA by 
Statins such as simvastatin, mevastatin, and 
lovastatin have been shown to decre- 
ase cell viability in several ovarian cancer cell 
lines [11, 28, 29]. Our recent results found that 
treatment with simvastatin in an orthotopic 
mouse model reduced ovarian tumor growth, 
coincident with decreased Ki-67, HMGCR, 
phosphorylated-Akt and phosphorylated-p42/ 
44 protein expression [11]. In the present 
study, our results indicate that ATO, similar to 
simvastatin, exhibits anti-tumorigenic activity 
in ovarian cancer cells through induction of 
apoptosis, cell cycle G1 arrest and autophagy. 
Furthermore, reduced cell proliferation by ATO 
was associated with inhibition of downstream 
targets of the mTOR and MAPK pathways. 
Intriguingly, inhibition of c-Myc by JQ1 syner-
Figure 6. JQ1 sensitized ATO in ovarian cancer cells. The cells were treated 
with different concentrations of ATO in media with 100 nM JQ1 for 72 h. MTT 
assays showed that JQ1 increased sensitivity to ATO (A). Western blotting 
showed that JQ1, ATO and the combination of JQ1 and ATO reduced expres-
sion of c-Myc (B). Inhibition of c-Myc by JQ1 significantly increased Annexin V 
expression (C) and cell cycle G1 arrest (D) induced by ATO in the cells after 
24 hours of treatment. Data are shown as mean + SEM of three experiments 
(*P < 0.05).
ATO significantly reduces the 
phosphorylation and activa-
tion of c-Myc [27]. We 
hypothesized that the inhibi-
tion of c-Myc by JQ1, a small 
molecular inhibitor for c-Myc, 
would increase the sensitivi-
ty of ovarian cancer cells to 
ATO. We conducted MTT 
assays which demonstrated 
that the combination of 100 
nM of JQ1 with ATO at varying 
concentrations resulted in 
synergistic inhibitory effects 
in both ovarian cancer cell 
lines after 72 hours of treat-
ment (Figure 6A, CI < 1). The 
combination of JQ1 and ATO 
significantly reduced the expre- 
ssion of c-Myc compared to 
the control (Figure 6B). We 
also found that combination 
treatment resulted in greater 
induction of apoptosis, as 
seen by increased annexin V 
expression as well as height-
ened cell cycle G1 arrest in 
both cell lines compared 
with the controls (Figure 6C, 
6D). These results support 
that the inhibition of c-Myc 
results in increased sensitiv-
ity of the ovarian cancer cells 
to ATO.
Discussion
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gized cellular sensitivity to ATO through induc-
tion of apoptosis and cell cycle arrest in ovarian 
cancer cells. Taken together, our data provide 
insight into the underlying mechanisms of ATO’s 
anti-proliferative effects in ovarian cancer cells 
and reveals a potential novel combination strat-
egy in this disease, i.e. inhibition of c-Myc com-
bined with ATO.
Previous investigators have shown that depri-
vation of mevalonate results in G1 phase cell 
cycle arrest in the MCF-7 breast cancer cells 
that is in part mediated by impaired activity of 
cyclin-dependent kinase 2 (CDK2) and decre- 
ased expression of positive regulators of G1 to 
S phase cell cycle progression [30]. Similarly, 
targeting HMG-COA by statins also induces 
malignant cells to undergo apoptosis and cell 
cycle arrest [31]. Many in vitro studies have 
shown that statins induce cell cycle G1 or S 
phase arrest in a time- and dose-dependent 
manner through affecting cell cycle regulatory 
proteins and activating apoptosis. Statins 
accomplish this anti-proliferative effect likely 
through inhibition of cholesterol synthesis and 
prenylation of G proteins [31]. Reduction of the 
proliferative capacity of colon cancer cells by 
ATO is associated with cell cycle G1 arrest via 
upregulation of p21(Cip1/Waf1), p27(Kip1) and 
phospho-JNK, downregulation of phosphos-
phorylated-AKT, hyperphosphorylation of Rb 
and activation of the caspase cascade [32, 33]. 
A recent phase II window-of-opportunity trial of 
ATO in breast cancer confirmed that ATO signifi-
cantly increases the expression of p27 and 
decreases cyclin D1 staining in tumor tissues, 
suggesting that cell cycle regulatory effects 
may contribute to anti-proliferative activity 
induced by ATO via cyclin D1 and p27 [34]. In 
our study, treating ovarian cancer cells with ATO 
induced cell cycle G1 phase arrest and 
increased the expression of annexin V and 
cleaved PARP in a dose-dependent manner. 
This is consistent with the proposed mecha-
nisms of action of ATO.
Autophagy is a cellular process of self-ingestion 
that delivers cytoplasmic contents to the lyso-
some. Autophagy plays an important role in bal-
ancing sources of energy and protecting cells in 
response to metabolic stress [35]. Inhibition of 
cell proliferation by simvastatin has been asso-
ciated with an increase in cellular ROS produc-
tion and induction of autophagy in breast can-
cer, lung cancer, lymphoma and ovarian cancer 
[36-38]. We found that ATO exhibits similar 
effects in induction of autophagy and cellular 
stress, which has also been reported in lym-
phoma and glioma cells [37, 39]. Additionally, a 
recent study found that ATO was also shown to 
elevate activity of autophagy and induce 
autophagy-associated cell death in PC3 pros-
tate cancer cells [40]. Our findings suggest that 
ATO functions to inhibit ovarian cancer prolifer-
ation, not only by affecting cell cycle and apop-
tosis, but also by inducing cellular stress and 
autophagy. The stress induced by ATO led to an 
increase in cellular ROS production, which was 
accompanied by increased AGT3 and AGT6 
expression and mitochondrial apoptosis, ulti-
mately leading to cell death in the ovarian can-
cer cell lines. Thus, our results suggest that 
inhibition of cell proliferation by ATO involves 
multiple cellular processes, along with its 
known targeting of HMGCR.
Several studies have suggested that the anti-
angiogenic and anti-metastatic activities of 
statins are achieved by inhibiting proliferation 
and migration of endothelial cells, inducing cell 
apoptosis and cellular stress, reducing cell 
migration and possibly impacting several sig-
naling pathways including the AKT/mTOR, p53, 
Rho and MAPK pathways, etc. [11, 41, 42]. It 
has been reported that treatment with ATO at a 
10 uM concentration can significantly decrease 
migration and invasion of U87 glioblastoma 
spheroid cells after 48 hours of treatment [43]. 
Treatment of non-small cell lung carcinoma 
cells with ATO also significantly inhibited VEGF 
expression both in vitro and in vivo by affecting 
ROS production [44]. Additionally, a recent 
study found that ATO reduced the pro-tumori-
genic effects of microglia on glioma migration 
and invasion by reducing the microglial expres-
sion of membrane type 1 metalloproteinase 
through the p38 MAPK pathway [45]. To deter-
mine whether ATO exerted anti-angiogenic and 
anti-metastatic activities in ovarian cancer 
cells, we used laminin-1 and transwell assays 
to access the capacity of adhesion and inva-
sion. As previously seen with simvastatin in 
ovarian cancer, ATO reduced ovarian cancer 
cell invasion and migration and inhibited VEGF 
protein expression in a dose-dependent 
manner. 
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Recent studies have implicated several signal-
ing pathways as mediators of statin-dependent 
anti-proliferative and pro-apoptotic effects [37, 
46]. Simvastatin has been found to activate 
AMP-activated protein kinase (AMPK), down-
regulate AKT and inhibit mTOR activity in glioma 
cells [46]. Fluvastatin induced apoptosis by 
increasing the activation of caspase-3 and by 
enhancing Bim expression through inhibition of 
the Ras/ERK and Ras/mTOR pathways in 
human head and neck squamous cell carcino-
ma cell lines [47]. ATO effectively suppressed 
anchorage-independent growth of ovarian can-
cer cells in soft agar along with activation of Jun 
N-terminal kinases (JNK) [48]. In this study, we 
examined the effect of ATO on the phosphoryla-
tion of AKT, ERK and S6, which are frequently 
overexpressed in many forms of ovarian can-
cer. Our findings reveal a significant decrease in 
S6 phosphorylation in both cell lines with an 
increase in AKT and ERK in the Hey cells and 
reduction of ERK phosphorylation in the SKOV3 
cells. The diverse effects of ATO on these sig-
naling pathways suggests that ATO inhibits cell 
proliferation via multiple signaling pathways in 
various ovarian cancer cells.
The activity of HMGCR regulates c-Myc phos-
phorylation via Rac. C-Myc phosphorylation is a 
critical mechanism by which the inhibition of 
HMG-CoA reductase by ATO mediates its anti-
neoplastic effects [27]. Inhibition of HMG-CoA 
reductase by ATO inhibits c-Myc phosphoryla-
tion and activation, resulting in blocked c-Myc-
induced initiation and growth of liver cancer 
and lymphomagenesis in vivo [27, 49]. Hence, 
we speculated that by inhibiting c-Myc activity 
using JQ1, ATO might enhance its anti-prolifera-
tive effect in ovarian cancer cells. After treating 
the ovarian cancer cells with different concen-
trations of ATO in combination with JQ1, we 
found that ATO reduced c-Myc expression after 
24 hours of treatment, yielding the lowest over-
all level of c-Myc with combination treatment. 
Importantly, inhibition of c-Myc activity by JQ1 
in combination with ATO exhibited a synergistic 
inhibitory effect through increasing of apopto-
sis and cell cycle G1 phase arrest in the Hey 
and SKOV3 cell lines (CI < 1). Together, these 
results suggest that inhibition of c-MYC activity 
appears to be a potential mechanism by which 
ATO inhibits cell viability in ovarian cancer cells. 
Currently, statins are being studied clinically for 
use in the prevention and treatment of cancer 
and as an adjuvant treatment in combination 
with chemotherapeutic agents [11]. ATO’s side 
effects are well tolerated in the long-term man-
agement of dyslipidemia, and multiple clinical 
trials have shown an acceptable safety profile 
at even high doses of ATO [39, 50, 51]. ATO at 
100 ppm (close to a clinically acceptable inter-
mediate dose range, 40 mg/d of atorvastatin) 
significantly blocks pancreatic carcinogenesis 
and increases survival in Pankras/p53 mice [52]. 
Combinations of atorvastatin (0.02% in diet) 
and celecoxib had a stronger inhibitory effect 
on the formation and growth of androgen-inde-
pendent LNCaP tumors than either drug alone 
in SCID mice [53]. Breast cancer patients who 
were given atorvastatin two weeks prior to sur-
gery showed anti-proliferative effects, with a 
decrease in Ki-67 staining in those tumors that 
were HMGCR positive [54]. These findings indi-
cate that ATO is a potential novel and well-toler-
ated chemotherapeutic agent for use in the 
prevention and treatment of cancers including 
ovarian cancer and warrants further investiga-
tion in clinical trials for ovarian cancer.
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